Compare FSBW & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBW | TENX |
|---|---|---|
| Founded | 1936 | 1967 |
| Country | United States | United States |
| Employees | 537 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.6M | 317.8M |
| IPO Year | 2011 | 2001 |
| Metric | FSBW | TENX |
|---|---|---|
| Price | $40.95 | $12.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $46.00 | $29.67 |
| AVG Volume (30 Days) | 10.6K | ★ 629.9K |
| Earning Date | 04-21-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $4,612,000.00 | N/A |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $10.47 | N/A |
| P/E Ratio | $40.29 | ★ N/A |
| Revenue Growth | ★ 44.80 | N/A |
| 52 Week Low | $36.72 | $5.34 |
| 52 Week High | $44.22 | $18.38 |
| Indicator | FSBW | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 54.98 | 44.63 |
| Support Level | $40.79 | $10.83 |
| Resistance Level | $40.97 | $14.15 |
| Average True Range (ATR) | 0.80 | 0.73 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 62.53 | 48.36 |
FS Bancorp Inc is the holding company of First Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.